Coronavirus: When will Merck and Pfizer pills come to Greece?
From next year we have in Greece the Merck pill for the coronavirus, while the corresponding preparation of Pfizer will follow in time, as the company is going to submit the data of the research to the FDA at the end of November.
«While the monoclonal antibodies we have this year, I do not think we have the Merck pill before the end of the yearDeputy Minister of Health Mina Gaga admitted.
The two drugs that are humanity’s powerful weapons against the voice virus, can play a critical role in changing the course of the pandemic, saving lives and reducing the severity of infections.
Reduction of hospitalization and death by 50% – Up to 1,000 euros the price
THE molnupiravir (molnupiravir) is an oral antiviral drug that inhibits the replication and proliferation of SARS-CoV-2 in the human body and reduces the risk of hospitalization or death by 50%.
The European Medicines Agency (EMA) says it is ready to recommend to EU Member States the emergency use of the objective pill against Covid-19 which jointly developed by Merck and Ridgeback Biotherapeutics, which was approved in the United Kingdom.
The EMA is also trying to speed up its assessment of the pill, which began last week before it could be marketed in the EU, as Europe faces a huge wave of infections.
“We will try to speed up our evaluation in order to get approval as soon as possible,” Marco Cavaleri, head of vaccine strategy at the EMA, told a news conference, adding that he could not give an exact date yet.
It is worth noting that the company has decided to sell the antiviral drug at the same price in Europe, whether the supply is made through the EU mechanism or by partial agreement. According to information, the price of each package will range from 700-1,000 euros.
At 89% the effectiveness of the Pfizer pill
Pfizer makes him that her coronavirus pill reduces the hospitalization and deaths of high-risk patients by 89%. The company’s share jumped 11% after the announcement.
This effect, according to a Bloomberg report, could radically change the treatment of Covid-19 and change the course of the pandemic.
The pharmaceutical industry has said it has stopped clinical trials of the treatment “because of its overwhelming effectiveness” and plans to submit the findings to US supervisory authorities for emergency permission as soon as possible.
Pfizer shares gain 11% in the session before the start of trading on Wall Street, while Merck fell 6.6%.
A Pfizer spokesman said the company would apply for a license to other regulators as soon as it submitted its application to the US authorities.
In the Pfizer clinical trial, which involved 1,219 unvaccinated adults, five days of treatment with her drug dramatically reduced the rate of hospitalizations when treatment was started within three or five days of the onset of symptoms.
Overall, only 0.8% of people who started treatment within three days of the onset of the disease ended up in hospital and no one died, while 7% of those who took placebo (placebo) during this time later ended up in hospital or they died.
Respectively were the results and when one started taking the pill within five days of the onset of symptoms.
Follow the Daily on Google News!